Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
Moderna, Inc. (NASDAQ:MRNA) has scheduled a live conference call for November 3, 2022, at 8:00 a.m. ET to discuss its Q3 2022 financial results and provide a corporate update. The call will be accessible via telephone with prior registration, and a live webcast will also be available on their website. Moderna has evolved from a research-stage company into a leader in mRNA therapeutics and vaccines, focusing on various diseases, including COVID-19. The archived webcast will be accessible for a year post-call.
- Leadership in mRNA therapeutics and vaccines.
- Established alliances with various domestic and global collaborators for manufacturing and science.
- None.
CAMBRIDGE, MA / ACCESSWIRE / October 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update.
To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website.
- Telephone: https://register.vevent.com/register/BI50e67285a997429fb4ca40ef36765c8a
- Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
https://www.accesswire.com/720142/Moderna-to-Report-Third-Quarter-2022-Financial-Results-on-Thursday-November-3-2022
FAQ
When will Moderna report its Q3 2022 financial results?
How can I access Moderna's Q3 2022 financial results conference call?
What significant developments has Moderna achieved in the past decade?
What is Moderna's primary focus area in its research?
